ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update

ALX Oncology Holdings Inc. (NASDAQ:ALXO) was the target of a significant drop in short interest in October. As of October 31st, there was short interest totalling 7,840,000 shares, a drop of 18.2% from the October 15th total of 9,590,000 shares. Currently, 25.9% of the company’s stock are short sold. Based on an average trading volume of 701,400 shares, the short-interest ratio is presently 11.2 days.

Institutional Trading of ALX Oncology

A number of institutional investors and hedge funds have recently modified their holdings of the company. Redmile Group LLC raised its holdings in ALX Oncology by 18.2% in the 1st quarter. Redmile Group LLC now owns 4,326,509 shares of the company’s stock worth $48,241,000 after acquiring an additional 667,245 shares during the period. Vanguard Group Inc. increased its stake in shares of ALX Oncology by 4.3% in the first quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock worth $17,466,000 after purchasing an additional 64,055 shares during the period. Marshall Wace LLP lifted its position in shares of ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after purchasing an additional 514,133 shares during the last quarter. Privium Fund Management B.V. boosted its stake in ALX Oncology by 28.2% during the 3rd quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock valued at $926,000 after purchasing an additional 112,093 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in ALX Oncology by 87.2% during the 2nd quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock valued at $2,642,000 after purchasing an additional 204,100 shares during the period. 97.97% of the stock is currently owned by institutional investors and hedge funds.

ALX Oncology Stock Down 3.0 %

ALXO opened at $1.29 on Friday. ALX Oncology has a twelve month low of $1.25 and a twelve month high of $17.83. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The business has a 50 day moving average price of $1.69 and a 200 day moving average price of $5.49. The firm has a market cap of $68.04 million, a P/E ratio of -0.43 and a beta of 1.03.

Analyst Ratings Changes

A number of research analysts have commented on the company. UBS Group lowered their target price on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, August 16th. Lifesci Capital downgraded ALX Oncology from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research report on Tuesday, November 12th. Stifel Nicolaus reissued a “hold” rating and issued a $3.00 target price (down from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of ALX Oncology in a report on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $12.50.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.